FibroBiologics shares rise 10.89% after-hours as Phase 1/2 trial site onboarding completed for CYWC628 diabetic foot ulcer treatment.

FibroBiologics surged 10.89% in after-hours trading following the announcement that it completed site onboarding for its Phase 1/2 clinical trial of CYWC628, an allogeneic fibroblast spheroid therapy for refractory diabetic foot ulcers. The multicenter, open-label study, managed by Southern Star Research, aims to evaluate safety, tolerability, and efficacy over 12 weeks, with an interim analysis after six weeks. The milestone signals progress in advancing the therapy toward potential commercialization, bolstering investor confidence in the company’s pipeline and its 270+ patent portfolio. The news aligns with FibroBiologics’ strategic focus on chronic wound care innovation, positioning the trial as a key catalyst for future data-driven growth.